Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed its 2004 annual report on March 10, 2005, detailing its financial condition and operational results for the period ending December 30, 2004. The company's primary focus remains on the development and commercialization of its proprietary antibody-based therapeutics. Investors should note the ongoing research and development activities, which are critical drivers of future growth and potential revenue streams. The company's pipeline and progress in clinical trials, particularly for key drug candidates, represent significant areas of interest for evaluating its long-term prospects.
Key Highlights
- 1The 10-K filing covers the fiscal year ending December 30, 2004, providing a comprehensive overview of Regeneron's business and financial performance.
- 2Regeneron's core strategy is centered on the discovery, development, and commercialization of novel antibody-based therapeutics.
- 3The report details the company's product pipeline and ongoing clinical trial activities, which are crucial for future revenue generation and market position.
- 4Financial statements provide a snapshot of the company's balance sheet, income statement, and cash flow for the years 2004, 2003, and 2002.
- 5The filing includes important disclosures regarding market risk and internal controls, essential for assessing operational integrity and financial stability.
- 6Various agreements, including manufacturing and collaboration agreements, are appended as exhibits, offering insight into key strategic partnerships and operational frameworks.
Frequently Asked Questions
This 10-K filing from March 2005 does not explicitly list all product candidates and their specific stages of development in a summarized format. Investors would need to refer to the detailed sections on 'Business' (Item 1) and potentially 'Management's Discussion and Analysis of Financial Condition and Results of Operations' (Item 7) for in-depth information on the company's pipeline, including key drug candidates in clinical trials.
The 'Selected Financial Data' (Item 6) and the detailed financial statements (Item 8) provide the key metrics for assessing financial health. Investors should examine revenue trends, net income or loss, cash flow from operations, and the balance sheet, paying close attention to cash reserves and any debt obligations to understand the company's financial stability and investment capacity.
Risks and uncertainties for a biopharmaceutical company like Regeneron typically include the inherent risks of drug development (e.g., clinical trial failures, regulatory approval delays), market competition, patent expirations, reliance on key personnel, and the ability to secure future funding. Specific details would be found in the 'Risk Factors' section, often within Item 1 or Item 1A, and also discussed in the 'Management's Discussion and Analysis' (Item 7).
The filing mentions various agreements as exhibits, including 'AMENDMENT NO. 1 TO COLLABORATION AGREEMENT' and manufacturing agreements. These indicate the presence of strategic partnerships. For details on the nature, scope, and financial implications of these collaborations, investors should consult Item 1 (Business) and review the specific exhibits referenced in Item 15.